tetano
Editor, Senior Moderator
Antimicrob Agents Chemother
. 2024 Jan 30:e0138423.
doi: 10.1128/aac.01384-23. Online ahead of print. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19
Hui Yang[SUP] #[/SUP][SUP] 1 2 [/SUP], Xin Yu[SUP] #[/SUP][SUP] 1 3 [/SUP], Wenjing Hou[SUP] #[/SUP][SUP] 2 4 [/SUP], Xiangduan Liu[SUP] #[/SUP][SUP] 2 5 [/SUP], Jiaojiao Chen[SUP] #[/SUP][SUP] 6 [/SUP], Ying Zhang[SUP] #[/SUP][SUP] 1 3 [/SUP], Ying Wang[SUP] 5 [/SUP], Ying Zhu[SUP] 1 [/SUP], Qing Qian[SUP] #[/SUP][SUP] 2 7 [/SUP], Kuifen Ma[SUP] #[/SUP][SUP] 2 8 [/SUP], Zhuoling An[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
Transplant patients face an elevated risk of coronavirus disease 2019 (COVID-19) morbidity and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted through the kidneys. The dosage of nirmatrelvir/ritonavir (NR) needs to be adjusted according to the degree of renal function impairment. Nevertheless, NR is not recommended for patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min) due to a dearth of associated research. In this study, we focus on kidney transplant patients and document and analyze the experiences of using NR in individuals with severe kidney dysfunction. This was a retrospective multicenter study that included transplant recipients hospitalized for COVID-19 in five major tertiary hospitals in China from December 2022 to June 2023. The outcomes consisted of the disease progression rate by day 28, individual disease progression events, safety outcomes, information on adverse events (AEs), and the blood drug concentrations of immunosuppressants. Data were presented with descriptive statistics. All analyses were performed using SPSS version 22. In total, 40 patients were included in the analysis. Considering the potential interaction between drugs, all patients temporarily discontinued their immunosuppressants during the NR treatment. None of the 32 moderate patients experienced disease progression. However, among the eight patients with critical COVID-19, unfortunately, two of them died. During the medication period, four patients experienced a total of six AEs associated with NR. None of them experienced AEs with a maximum grade of ≥3. Blood drug concentrations of immunosuppressants were monitored in 22 of 40 patients, and the blood drug concentrations of immunosuppressants did not show a significant increase, but some patients experienced lower blood drug concentrations. Our findings supported the use of NR therapy for the treatment of COVID-19 in transplant patients with severe renal insufficiency. A modified dose of NR was well-tolerated.
Keywords: COVID-19; kidney transplant; nirmatrelvir/ritonavir; severe kidney dysfunction.
. 2024 Jan 30:e0138423.
doi: 10.1128/aac.01384-23. Online ahead of print. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19
Hui Yang[SUP] #[/SUP][SUP] 1 2 [/SUP], Xin Yu[SUP] #[/SUP][SUP] 1 3 [/SUP], Wenjing Hou[SUP] #[/SUP][SUP] 2 4 [/SUP], Xiangduan Liu[SUP] #[/SUP][SUP] 2 5 [/SUP], Jiaojiao Chen[SUP] #[/SUP][SUP] 6 [/SUP], Ying Zhang[SUP] #[/SUP][SUP] 1 3 [/SUP], Ying Wang[SUP] 5 [/SUP], Ying Zhu[SUP] 1 [/SUP], Qing Qian[SUP] #[/SUP][SUP] 2 7 [/SUP], Kuifen Ma[SUP] #[/SUP][SUP] 2 8 [/SUP], Zhuoling An[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
- PMID: 38289075
- DOI: 10.1128/aac.01384-23
Transplant patients face an elevated risk of coronavirus disease 2019 (COVID-19) morbidity and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted through the kidneys. The dosage of nirmatrelvir/ritonavir (NR) needs to be adjusted according to the degree of renal function impairment. Nevertheless, NR is not recommended for patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min) due to a dearth of associated research. In this study, we focus on kidney transplant patients and document and analyze the experiences of using NR in individuals with severe kidney dysfunction. This was a retrospective multicenter study that included transplant recipients hospitalized for COVID-19 in five major tertiary hospitals in China from December 2022 to June 2023. The outcomes consisted of the disease progression rate by day 28, individual disease progression events, safety outcomes, information on adverse events (AEs), and the blood drug concentrations of immunosuppressants. Data were presented with descriptive statistics. All analyses were performed using SPSS version 22. In total, 40 patients were included in the analysis. Considering the potential interaction between drugs, all patients temporarily discontinued their immunosuppressants during the NR treatment. None of the 32 moderate patients experienced disease progression. However, among the eight patients with critical COVID-19, unfortunately, two of them died. During the medication period, four patients experienced a total of six AEs associated with NR. None of them experienced AEs with a maximum grade of ≥3. Blood drug concentrations of immunosuppressants were monitored in 22 of 40 patients, and the blood drug concentrations of immunosuppressants did not show a significant increase, but some patients experienced lower blood drug concentrations. Our findings supported the use of NR therapy for the treatment of COVID-19 in transplant patients with severe renal insufficiency. A modified dose of NR was well-tolerated.
Keywords: COVID-19; kidney transplant; nirmatrelvir/ritonavir; severe kidney dysfunction.